Overview

• US medical technology firm's Q1 revenue rose 2.4%, beating analyst expectations

• Adjusted EPS for Q1 beat consensus

• Company reaffirmed 2026 revenue guidance and raised adjusted EPS outlook

Outlook

• Integra Lifesciences expects Q2 revenue between $410 mln and $425 mln

• Company sees Q2 adjusted EPS in a range of $0.44 to $0.52

• Integra Lifesciences raises 2026 adj EPS guidance to $2.40-$2.50, reaffirms revenue outlook

Result Drivers

• TISSUE RECONSTRUCTION GROWTH - Strong growth in Integra Skin, DuraSorb, and the relaunch of PriMatrix drove mid-single digit growth in wound reconstruction; private label sales also rose, per company

• SUPPLY RELIABILITY - Improved supply reliability supported strong growth in Integra Skin and return to market with PriMatrix and Durepair, according to CEO Stuart Essig

• SEGMENT PERFORMANCE MIX - Organic growth in Neuro was offset by declines in Instruments and ENT, with instrument sales affected by order timing, per company

Company press release: ID:nGNX9NlFFj

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q1 Revenue	Beat	$391.9 mln	$381.87 mln (8 Analysts)
Q1 Adjusted EPS	Beat	$0.54	$0.40 (8 Analysts)
Q1 EPS		-$0.06
Q1 Adjusted Net Income		$41.6 mln
Q1 Adjusted EBITDA		$76.2 mln
Q1 Adjusted Gross Margin		64.1%

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 5 "hold" and 3 "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

• Wall Street's median 12-month price target for Integra Lifesciences Holdings Corp is $13.00, about 22.1% above its May 4 closing price of $10.65

• The stock recently traded at 4 times the next 12-month earnings vs. a P/E of 5 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.